Selected research
Market Structure
Global Congestive Heart Failure Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Congestive Heart Failure Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Congestive Heart Failure Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Congestive Heart Failure Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Congestive Heart Failure Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Congestive Heart Failure Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Congestive Heart Failure Drugs include Sanofi, Johnson & Johnson, Novartis, Merck & Co, Mylan, Pfizer, GSK, Bayer and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Congestive Heart Failure Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Congestive Heart Failure Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Congestive Heart Failure Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Congestive Heart Failure Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Congestive Heart Failure Drugs Segment by Company
Sanofi
Johnson & Johnson
Novartis
Merck & Co
Mylan
Pfizer
GSK
Bayer
AstraZeneca
Xudong Haipu Pharmaceutical
Xinhua Group
Sinepharm
NCPC
Lunan Pharmaceutical
Langtian
Hayao
Hai Ni Pharmaceutical
Exelixis
CRC
Bristol-Myers Squibb
Boehringer Inhelheim
Bausch Health
Congestive Heart Failure Drugs Segment by Type
Capsule
Tablets
Injection
Congestive Heart Failure Drugs Segment by Application
Clinic
Hospital
Household
Other
Congestive Heart Failure Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Congestive Heart Failure Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Congestive Heart Failure Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Congestive Heart Failure Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Congestive Heart Failure Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Congestive Heart Failure Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Congestive Heart Failure Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Congestive Heart Failure Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Capsule
- Tablets
- Injection
Applications
- Clinic
- Hospital
- Household
- Other
Companies covered
- Sanofi
- Johnson & Johnson
- Novartis
- Merck & Co
- Mylan
- Pfizer
- GSK
- Bayer
- AstraZeneca
- Xudong Haipu Pharmaceutical
- Xinhua Group
- Sinepharm
- NCPC
- Lunan Pharmaceutical
- Langtian
- Hayao
- Hai Ni Pharmaceutical
- Exelixis
- CRC
- Bristol-Myers Squibb
- Boehringer Inhelheim
- Bausch Health
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Congestive Heart Failure Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Congestive Heart Failure Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Congestive Heart Failure Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Congestive Heart Failure Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Congestive Heart Failure Drugs Market Dynamics
- 2.1 Congestive Heart Failure Drugs Industry Trends
- 2.2 Congestive Heart Failure Drugs Industry Drivers
- 2.3 Congestive Heart Failure Drugs Industry Opportunities and Challenges
- 2.4 Congestive Heart Failure Drugs Industry Restraints
3 Congestive Heart Failure Drugs Market by Manufacturers
- 3.1 Global Congestive Heart Failure Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Congestive Heart Failure Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Congestive Heart Failure Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Congestive Heart Failure Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Congestive Heart Failure Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Congestive Heart Failure Drugs Manufacturers, Product Type & Application
- 3.7 Global Congestive Heart Failure Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Congestive Heart Failure Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Congestive Heart Failure Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Congestive Heart Failure Drugs Tier 1, Tier 2, and Tier 3
4 Congestive Heart Failure Drugs Market by Type
- 4.1 Congestive Heart Failure Drugs Type Introduction
- 4.1.1 Capsule
- 4.1.2 Tablets
- 4.1.3 Injection
- 4.2 Global Congestive Heart Failure Drugs Sales by Type
- 4.2.1 Global Congestive Heart Failure Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Congestive Heart Failure Drugs Sales by Type (2021-2032)
- 4.2.3 Global Congestive Heart Failure Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Congestive Heart Failure Drugs Revenue by Type
- 4.3.1 Global Congestive Heart Failure Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Congestive Heart Failure Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Congestive Heart Failure Drugs Revenue Market Share by Type (2021-2032)
5 Congestive Heart Failure Drugs Market by Application
- 5.1 Congestive Heart Failure Drugs Application Introduction
- 5.1.1 Clinic
- 5.1.2 Hospital
- 5.1.3 Household
- 5.1.4 Other
- 5.2 Global Congestive Heart Failure Drugs Sales by Application
- 5.2.1 Global Congestive Heart Failure Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Congestive Heart Failure Drugs Sales by Application (2021-2032)
- 5.2.3 Global Congestive Heart Failure Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Congestive Heart Failure Drugs Revenue by Application
- 5.3.1 Global Congestive Heart Failure Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Congestive Heart Failure Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Congestive Heart Failure Drugs Revenue Market Share by Application (2021-2032)
6 Global Congestive Heart Failure Drugs Sales by Region
- 6.1 Global Congestive Heart Failure Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Congestive Heart Failure Drugs Sales by Region (2021-2032)
- 6.2.1 Global Congestive Heart Failure Drugs Sales by Region (2021-2026)
- 6.2.2 Global Congestive Heart Failure Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Congestive Heart Failure Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Congestive Heart Failure Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Congestive Heart Failure Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Congestive Heart Failure Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Congestive Heart Failure Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Congestive Heart Failure Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Congestive Heart Failure Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Congestive Heart Failure Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Congestive Heart Failure Drugs Revenue by Region
- 7.1 Global Congestive Heart Failure Drugs Revenue by Region
- 7.1.1 Global Congestive Heart Failure Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Congestive Heart Failure Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Congestive Heart Failure Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Congestive Heart Failure Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Congestive Heart Failure Drugs Revenue (2021-2032)
- 7.2.2 North America Congestive Heart Failure Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Congestive Heart Failure Drugs Revenue (2021-2032)
- 7.3.2 Europe Congestive Heart Failure Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Congestive Heart Failure Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Congestive Heart Failure Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Congestive Heart Failure Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Congestive Heart Failure Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Sanofi
- 8.1.1 Sanofi Company Information
- 8.1.2 Sanofi Business Overview
- 8.1.3 Sanofi Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Sanofi Congestive Heart Failure Drugs Product Portfolio
- 8.1.5 Sanofi Recent Developments
- 8.2 Johnson & Johnson
- 8.2.1 Johnson & Johnson Company Information
- 8.2.2 Johnson & Johnson Business Overview
- 8.2.3 Johnson & Johnson Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Johnson & Johnson Congestive Heart Failure Drugs Product Portfolio
- 8.2.5 Johnson & Johnson Recent Developments
- 8.3 Novartis
- 8.3.1 Novartis Company Information
- 8.3.2 Novartis Business Overview
- 8.3.3 Novartis Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Novartis Congestive Heart Failure Drugs Product Portfolio
- 8.3.5 Novartis Recent Developments
- 8.4 Merck & Co
- 8.4.1 Merck & Co Company Information
- 8.4.2 Merck & Co Business Overview
- 8.4.3 Merck & Co Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Merck & Co Congestive Heart Failure Drugs Product Portfolio
- 8.4.5 Merck & Co Recent Developments
- 8.5 Mylan
- 8.5.1 Mylan Company Information
- 8.5.2 Mylan Business Overview
- 8.5.3 Mylan Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Mylan Congestive Heart Failure Drugs Product Portfolio
- 8.5.5 Mylan Recent Developments
- 8.6 Pfizer
- 8.6.1 Pfizer Company Information
- 8.6.2 Pfizer Business Overview
- 8.6.3 Pfizer Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Pfizer Congestive Heart Failure Drugs Product Portfolio
- 8.6.5 Pfizer Recent Developments
- 8.7 GSK
- 8.7.1 GSK Company Information
- 8.7.2 GSK Business Overview
- 8.7.3 GSK Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 GSK Congestive Heart Failure Drugs Product Portfolio
- 8.7.5 GSK Recent Developments
- 8.8 Bayer
- 8.8.1 Bayer Company Information
- 8.8.2 Bayer Business Overview
- 8.8.3 Bayer Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Bayer Congestive Heart Failure Drugs Product Portfolio
- 8.8.5 Bayer Recent Developments
- 8.9 AstraZeneca
- 8.9.1 AstraZeneca Company Information
- 8.9.2 AstraZeneca Business Overview
- 8.9.3 AstraZeneca Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 AstraZeneca Congestive Heart Failure Drugs Product Portfolio
- 8.9.5 AstraZeneca Recent Developments
- 8.10 Xudong Haipu Pharmaceutical
- 8.10.1 Xudong Haipu Pharmaceutical Company Information
- 8.10.2 Xudong Haipu Pharmaceutical Business Overview
- 8.10.3 Xudong Haipu Pharmaceutical Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Xudong Haipu Pharmaceutical Congestive Heart Failure Drugs Product Portfolio
- 8.10.5 Xudong Haipu Pharmaceutical Recent Developments
- 8.11 Xinhua Group
- 8.11.1 Xinhua Group Company Information
- 8.11.2 Xinhua Group Business Overview
- 8.11.3 Xinhua Group Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Xinhua Group Congestive Heart Failure Drugs Product Portfolio
- 8.11.5 Xinhua Group Recent Developments
- 8.12 Sinepharm
- 8.12.1 Sinepharm Company Information
- 8.12.2 Sinepharm Business Overview
- 8.12.3 Sinepharm Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Sinepharm Congestive Heart Failure Drugs Product Portfolio
- 8.12.5 Sinepharm Recent Developments
- 8.13 NCPC
- 8.13.1 NCPC Company Information
- 8.13.2 NCPC Business Overview
- 8.13.3 NCPC Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 NCPC Congestive Heart Failure Drugs Product Portfolio
- 8.13.5 NCPC Recent Developments
- 8.14 Lunan Pharmaceutical
- 8.14.1 Lunan Pharmaceutical Company Information
- 8.14.2 Lunan Pharmaceutical Business Overview
- 8.14.3 Lunan Pharmaceutical Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Lunan Pharmaceutical Congestive Heart Failure Drugs Product Portfolio
- 8.14.5 Lunan Pharmaceutical Recent Developments
- 8.15 Langtian
- 8.15.1 Langtian Company Information
- 8.15.2 Langtian Business Overview
- 8.15.3 Langtian Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 Langtian Congestive Heart Failure Drugs Product Portfolio
- 8.15.5 Langtian Recent Developments
- 8.16 Hayao
- 8.16.1 Hayao Company Information
- 8.16.2 Hayao Business Overview
- 8.16.3 Hayao Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 Hayao Congestive Heart Failure Drugs Product Portfolio
- 8.16.5 Hayao Recent Developments
- 8.17 Hai Ni Pharmaceutical
- 8.17.1 Hai Ni Pharmaceutical Company Information
- 8.17.2 Hai Ni Pharmaceutical Business Overview
- 8.17.3 Hai Ni Pharmaceutical Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 Hai Ni Pharmaceutical Congestive Heart Failure Drugs Product Portfolio
- 8.17.5 Hai Ni Pharmaceutical Recent Developments
- 8.18 Exelixis
- 8.18.1 Exelixis Company Information
- 8.18.2 Exelixis Business Overview
- 8.18.3 Exelixis Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.18.4 Exelixis Congestive Heart Failure Drugs Product Portfolio
- 8.18.5 Exelixis Recent Developments
- 8.19 CRC
- 8.19.1 CRC Company Information
- 8.19.2 CRC Business Overview
- 8.19.3 CRC Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.19.4 CRC Congestive Heart Failure Drugs Product Portfolio
- 8.19.5 CRC Recent Developments
- 8.20 Bristol-Myers Squibb
- 8.20.1 Bristol-Myers Squibb Company Information
- 8.20.2 Bristol-Myers Squibb Business Overview
- 8.20.3 Bristol-Myers Squibb Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.20.4 Bristol-Myers Squibb Congestive Heart Failure Drugs Product Portfolio
- 8.20.5 Bristol-Myers Squibb Recent Developments
- 8.21 Boehringer Inhelheim
- 8.21.1 Boehringer Inhelheim Company Information
- 8.21.2 Boehringer Inhelheim Business Overview
- 8.21.3 Boehringer Inhelheim Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.21.4 Boehringer Inhelheim Congestive Heart Failure Drugs Product Portfolio
- 8.21.5 Boehringer Inhelheim Recent Developments
- 8.22 Bausch Health
- 8.22.1 Bausch Health Company Information
- 8.22.2 Bausch Health Business Overview
- 8.22.3 Bausch Health Congestive Heart Failure Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.22.4 Bausch Health Congestive Heart Failure Drugs Product Portfolio
- 8.22.5 Bausch Health Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Congestive Heart Failure Drugs Value Chain Analysis
- 9.1.1 Congestive Heart Failure Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Congestive Heart Failure Drugs Production Mode & Process
- 9.2 Congestive Heart Failure Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Congestive Heart Failure Drugs Distributors
- 9.2.3 Congestive Heart Failure Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst